Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.aartidrugs.com | |
Market Cap | 3,885.50 Cr. | |
Enterprise Value(EV) | 4,466.67 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 17.88 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | 23.46 | Trailing Twelve Months Ending 2022-12 |
Industry PE | 32.22 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 123.82 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 3.39 | Calculated using Price: 419.50 |
Dividend Yield | 0.24 | Period Ending 2022-03 |
No. of Shares Subscribed | 9.26 Cr. | 92,600,000 Shares |
FaceValue | 10 | |
Company Profile | ||
Aarti Drugs (ADL), incorporated in 1984, is engaged in the business of manufacturing generic bulk actives, advanced intermediates and specialty chemicals. The company is part of $265 million Aarti Group of Industries. |
1 Day |
|
+4.33% |
1 Week |
|
+2.18% |
1 Month |
|
-6.85% |
3 Month |
|
-9.59% |
6 Month |
|
+0.62% |
1 Year |
|
-18.23% |
2 Year |
|
-38.90% |
5 Year |
|
+183.60% |
10 Year |
|
+1400.36% |
9 years | 2011-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 15.18 | 32.78 | 20.65 | 21.60 | 19.24 | 17.97 | 23.65 | 35.81 | 21.03 | |
Return on Capital Employed (%) | 13.12 | 23.93 | 17.95 | 18.50 | 17.31 | 17.01 | 21.39 | 34.52 | 20.75 | |
Return on Assets (%) | 4.99 | 10.13 | 6.53 | 7.13 | 6.38 | 6.31 | 9.33 | 16.78 | 10.32 |
Particulars | 10 years | 2011-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 163 | 308 | 357 | 400 | 455 | 543 | 652 | 913 | 1,036 | 1,110 | |
Non Curr. Liab. | 290 | 211 | 244 | 297 | 312 | 321 | 301 | 257 | 232 | 225 | |
Curr. Liab. | 70 | 483 | 501 | 494 | 622 | 591 | 623 | 595 | 940 | 934 | |
Minority Int. | 0 | 0 | 0 | ||||||||
Equity & Liab. | 523 | 1,002 | 1,102 | 1,191 | 1,389 | 1,455 | 1,577 | 1,766 | 2,208 | 2,269 | |
Non Curr. Assets | 264 | 476 | 537 | 620 | 653 | 671 | 673 | 709 | 815 | 869 | |
Curr. Assets | 260 | 526 | 565 | 571 | 737 | 784 | 904 | 1,057 | 1,393 | 1,400 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 523 | 1,002 | 1,102 | 1,191 | 1,389 | 1,455 | 1,577 | 1,766 | 2,208 | 2,269 |
Particulars | 10 years | 2011-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 501 | 1,097 | 1,140 | 1,195 | 1,244 | 1,561 | 1,806 | 2,155 | 2,489 | 2,668 | |
Other Income | 0 | 1 | 4 | 1 | 2 | 1 | 5 | 11 | 4 | ||
Total Income | 501 | 1,098 | 1,140 | 1,199 | 1,245 | 1,563 | 1,808 | 2,159 | 2,500 | 2,672 | |
Total Expenditure | -432 | -925 | -960 | -1,005 | -1,042 | -1,350 | -1,541 | -1,714 | -2,156 | -2,370 | |
PBIDT | 69 | 173 | 180 | 194 | 203 | 213 | 267 | 445 | 344 | 302 | |
Interest | -17 | -42 | -48 | -40 | -38 | -44 | -37 | -26 | -24 | -31 | |
Depreciation | -19 | -31 | -37 | -38 | -40 | -43 | -49 | -50 | -50 | -50 | |
Taxation | -10 | -22 | -27 | -34 | -42 | -41 | -44 | -89 | -65 | -56 | |
Exceptional Items | 4 | 4 | 0 | ||||||||
PAT | 24 | 77 | 69 | 82 | 82 | 90 | 141 | 280 | 205 | 166 | |
Minority Interest | 0 | 0 | 0 | ||||||||
Share Associate | 0 | ||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 24 | 77 | 69 | 82 | 82 | 90 | 141 | 280 | 205 | 166 | |
Adjusted EPS | 2 | 8 | 7 | 9 | 9 | 10 | 15 | 30 | 22 | 18 |
Particulars | 10 years | 2010-03 Rs. Cr. | 2011-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 59 | 21 | 105 | 133 | 175 | 70 | 143 | 251 | 155 | 70 | |
Cash Fr. Inv. | -30 | -76 | -107 | -99 | -107 | -74 | -62 | -33 | -72 | -149 | |
Cash Fr. Finan. | -24 | 53 | 1 | -33 | -68 | 4 | -80 | -215 | -81 | 92 | |
Net Change | 5 | -3 | -1 | 1 | 0 | 0 | 1 | 2 | 2 | 13 | |
Cash & Cash Eqvt | 9 | 5 | 4 | 5 | 3 | 3 | 5 | 7 | 9 | 22 |
Fri, 03 Feb 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Transcript of Q3 FY23 Earning Conference Call |
Mon, 30 Jan 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Recording of Conference Call |
Fri, 27 Jan 2023
Board Meeting Outcome for Compliance Of Regulation 42(1)(A) And Regulation 43 Of The SEBI (LODR) Regulations 2015. We wish to inform you that the Board of Directors of the Company at its Meeting held on Friday January 27 2023 has declared the Interim Dividend of Re. 1/- (Rupee One) (@10%) per Equity share of Rs. 10/- each for the financial year 2022-23 |
Fri, 03 Feb 2023 |
|
|
|
|
|